To present long-term clinical outcomes of patients with central serous chorioretinopathy (CSCR) followed in a single tertiary Centre.

Patients and Methods:

Forty-two patients diagnosed as acute or chronic CSCR and followed regularly were included into the study. The files of the patients with complete follow-up data were reviewed retrospectively and following parameters were recorded: Age, gender, type, symptom durations, episode numbers, imaging features, treatment options, episode durations, best corrected visual acuity at baseline and visits, intraocular pressure (IOP), precipitating factors and systemic associations. Optic coherence tomography (OCT), fundus fluoresceine angiography (FFA) in all patients and indocyanine green angiography (ICG) and autofluoresence imaging in some patients were obtained.


There were 32 male (%76.2) and 10 female (%23.8). Mean age was 44.1 ±11.4 years old (27-70 years). Mean symptom duration was 57.3 ±10.2 days. Twenty-seven cases were acute CSCR and remaining 15 were chronic CSCR. Majority of patient had monofocal-leaking site. Recurrent attack number varied from no recurrence to 3. Minority of patients had precipitating factor or chronic systemic illness. Baseline, month 3, month 6, month 12 and final Snellen BCVA was 0.56±0.24 (0.05 to 1.0), 0.58±0.25, 0.63±0.25 and 0.64±0.33 and 0.65±0.30, respectively. Baseline thickness of subretinal fluid was 194.1±113.6 (52 to 450)μm. Central macular thickness during the follow-up was: 404.4±123.9μm at baseline, 299.5±97.8μm at month 3; 269.7±62.3μm at month 6; 270.3±53.4 μm at month 12 and 322.1±104.9 μm at final visit. Mean IOP was 15.1±1.9mmHg at baseline and 14.6±1.9mmHg at month 12. Twenty-one patients required two session of treatment while 10 patients required one treatment except topical medications. Only three patients opted observation alone. Eight patients underwent topical treatment and observation. Five patients underwent laser photocoagulation of leaking site with or without additional topical treatment. Eighteen patients underwent photodynamic therapy (PDT) and maximum number of PDT for one patient was 2. Five patients received systemic therapy with oral mineralocorticoid antagonist agent. Seven patients underwent intravitreal anti-VEGF injections with or without subsequent other treatments. Nobody was treated with micropulse laser treatment in this series. Mean follow-up was 16.5±17.5 (6-72) months.


Although no approved evidence based treatment guidelines for CSCR exists, many patients respond well to current various treatment options with relatively good prognosis.

Contact Details:

Email:  uuinan@gmail.com
Cell Phone: +905323248889